The use of enteral formulas enriched with BCAAs is best used for patients with:

• A. Cirrhosis
• B. Hepatic failure
• C. Liver transplantation
• D. Refractory encephalopathy

Answer: (D)

Branched-chain amino acid–enriched enteral formulas are used to address hepatic encephalopathy by rebalance of amino acids that influence brain function. In liver failure, aromatic amino acids rise and can contribute to neurotoxicity and altered neurotransmission; increasing BCAAs helps compete for transport into the brain and supports neurotransmitter balance and protein synthesis. This approach is most valuable when encephalopathy does not respond to standard treatments or dietary protein adjustments—refractory hepatic encephalopathy—making it the best option among the scenarios listed. While cirrhosis or hepatic failure can involve encephalopathy, the strongest indication for BCAA-enriched formulas is persistent, difficult-to-treat HE; after liver transplantation, encephalopathy typically improves on its own, so this is not the primary scenario for their use.